secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001104659-26-017134
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma prices $4.0M public offering of common stock and warrants
--------------------------------------------------------------------------

- Offering of 13.8M shares/pre-funded warrants and warrants for up to 20.7M shares at combined $0.29 per unit.
- Gross proceeds ~$4.0M; net proceeds ~$3.46M after placement agent fees and expenses.
- Warrants exercisable immediately at $0.29 per share, expire 5 years from issuance.
- Placement agent Maxim Group LLC receives 8% cash fee, $100K expense reimbursement, and 690,650 warrant shares at $0.319.
- Directors and officers subject to 180-day lock-up; company restricted from certain equity issuances for 180 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/0001104659-26-017134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926017134/tm266571d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer